Citizens JMP Reiterates Market Outperform Rating on LeMaitre Vascular (LMAT)

Citizens JMP analyst Daniel Stauder reiterated a Market Outperform rating and $113.00 price target on LeMaitre Vascular (NASDAQ: LMAT).

The analyst commented, “We reiterate our Market Outperform rating and $113 price target on shares of LeMaitre Vascular ahead of the company's 2Q25 earnings results, which will be released after the market close on August 5th. We note that LMAT raised its top-line FY25 guidance a healthy 300 bps (to +13% y/y organic in FY25) on its 1Q25 call, accompanied by tweaks lower on the operating margin and EPS line, which primarily reflected LMAT's accelerated expansion of its sales reps during the first quarter (+12 to 164 from 152). With this in mind, we view these guidance updates more so as a factor of timing, and as these new adds ramp up and improve utilization throughout the year, top- and bottom-line results have the potential for upside. We also highlight that the company's list price increases have shown early progress (ASP added 9% to total sales in 1Q25), giving us further confidence in LMAT's potential to drive sales growth and operating leverage through 2025 and 2026.”

For an analyst ratings summary and ratings history on LeMaitre Vascular click here. For more ratings news on LeMaitre Vascular click here.

Shares of LeMaitre Vascular closed at $82.43 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)